1. Thomas S. Bundt, PhD., FACHE COL, MS Commander, USAMRIID
Contracting Opportunities at USAMRIID
20 November 2015
Disclaimer: Opinions, interpretations, conclusions, and recommendations are those of the presenter and are not necessarily endorsed by the U.S. Army.

2. Discussion Topics Who is USAMRIID What kinds of programs do we support
Mission & Vision of the Laboratory
Core Competencies
What kinds of programs do we support
Medical Biological Defense Countermeasure Research & Development
What do we procure and how do we procure it
Commercial Goods
Services
R&D
Who are the contacts at USAMRIID
Logistics & Procurement
Research & Development

3. USAMRIID Mission and Vision
Provide leading edge medical capabilities to deter and defend against current and emerging biological threat agents
Vision
To be the leader in the advancement of medical biological defense with world renowned experts dedicated to protecting our military forces and the nation
Main points:
Established by General Order No. 6, 27 January 1969, Office of the Surgeon General of the Army
$480 Million in facilities and equipment
~900 Personnel military, civilian and contractor
Over 200 physicians, veterinarians, and Ph.D. scientists from all allied medical sciences
The unique national capabilities of USAMRIID in Biodefense are expensive to maintain
Historically, the Biodefense program has provided the majority of the funding, and the transfer of program funding responsibilities from Army to ATSD(NCB) in 1994 and from NCB to DTRA in 2003 have not changed this.
The Army’s core competencies and infrastructure supporting the MCBDP extend beyond RIID to other USAMRMC laboratories and the HQ. USAMRIID can not be effective as a stand alone lab.
There are no sources of available Army S&T funding to supplant the OSD funding. The total of Army medical S&T (infectious disease, combat casualty care and military operational medicine) is equivalent to the MCBDP, and those funds are invested in internal laboratory operations at a higher percentage than the MCBDP.
New NHP holding facility 13,000 GSF with 384 NHP capacity. Currently BSL-2.
Medical Biological Defense Insurance Policy for the Nation

4. Core Competencies Prepare for Uncertainty Rapidly Identify
Biologic Agents
Provide World Class Expertise in Medical Biological Defense
Train & Educate
the Force
Develop, Test & Evaluate
Medical Countermeasures
Biosafety & Biosecurity 4

5. Full Spectrum of Medical Biodefense Support
PREVENTION
DETECTION
DIAGNOSIS
TREATMENT
MINUTES
MONTHS
HOURS
DAYS
YEARS
PLANNING OPPORTUNITY
REACTIVE
Attack
BIOLOGICAL
DEFENSE
VACCINES
DRUGS
IMMUNE GLOBULINS
Diagnostics

6. Medical Countermeasure Research & Development
Industry
Universities
Pharma
Biotech
HHS
Research
Product Evaluation
Large-scale, medical product-evaluation capability
Animal model development
High-containment labs and animal facilities
Aerosol exposures
FDA-regulated studies
Efficacy
Testing
DoD
DHS
HOW THIS SLIDE WORKS
THE TOP ROW is a pictorial overview of the Medical R&D process
Pharmaceutical research and development is a lengthy expensive process that can take a commercial pharmaceutical company 20 years and $850M on average to yield one licensed drug.
Research -- is basic science and discovery
Learning about how a disease processes works and discovering ways to control it.
This photo here is of a high-throughput screening (HTS) production line that is capable of testing hundreds of thousands compounds looking for hits. One component of discovering promising countermeasures.
Development – is the applied science of turning discoveries into useful products.
The picture here shows a industrial fermenter capable of manufacturing vaccines
Medical Product Testing – is the link between them
Before a promising vaccine or drug can be licensed for use, it undergoes rigorous testing for safety and efficacy.
Candidate vaccines and drugs must be proven safe and effective first in animals
This is USAMRIID’s forte.
If you have a promising vaccine for smallpox or Ebola, you have to come to USAMRIID to test it.
This photo in the center shows several non-human primates undergoing tests for the new Ebola vaccine.
USAMRIID is at a critical juncture in the interagency pipeline for biodefense R&D
UPSTREAM increase investment in basic research and discovery phase
Should produce a surge in promising candidate vaccines and drugs that need to be tested.
DOWNSTREAM – Increased financial incentives for advanced development and stockpiling
MIDSTREAM – Need proportional investment in the future for medical testing
INCREASING DEMAND FOR USAMRIID’s UNIQUE CAPABILITIES
USAMRIID has already seen agreements with government, academia, and industry expand rapidly since 2000, doubling and tripling year over year since year 2000.
Animal studies increase X 3
Diagnostic studies increase X 8
Agreements with government X 3; academia X 3; industry X 3

7. What Do We Procure to Support our Mission?
Commercial Goods
Lab materials and supplies, capital equipment (administrative and scientific), administrative materials and supplies, animals and animal supplies
Construction Services
Renovation
Research Services
CFR-regulated research and development services (GLP, cGMP), laboratory testing, DNA sequencing, protein expression & purification
Consultants, non-personal services
Research & Development
Innovative R&D integrated with in-house research projects in support USAMRIID’s core program

8. How Do We Obtain Products and Services ?
Commercial Items & Commercial Services
Credit Card Orders
Established Contracts
New Contracts
R&D
Contracts (Procurement, SBIR, STTR)
Grants & Cooperative Agreements (BAA)
Cooperative Research and Development Agreements (CRDA)
Commercial Test Agreements (CTA)
Interagency Agreements

9. How Much Do We Acquire ? Service contracts (USAMRAA)
Approximately $50M
Expendable medical – lab supplies, reagents (USAMRAA)
Approximately $2.3M
Expendable medical - credit card (USAMRIID)
Approximately $10.4M
Equipment Maintenance (USAMRAA)
Approximately $6.2M
Equipment Procurement (USAMRAA)
Approximately $9.8M
R & D (Contracts, Grants & Cooperative Agreements - USAMRAA)
Approximately $3M - $11M
7. Construction – Renovation (USAMRAA - USACE)
Approximately $3M - $10M

10. Where to look for procurement opportunities

11. USAMRIID POCs Logistics & Procurement Research & Development
Ms. Beverly Williams
Chief, Logistics Division
USAMRIID
Research & Development
Ms. Cindy K. Fuchs, J.D.
Director, Office of Research & Technology Applications

12. USAMRIID In 2017
NIAID IRF BSL3/4 147K GSF staff
NBACC BSL3/4 160K GSF 120 staff
New RIID BSL3/4 835K GSF staff
$511M construction cost
Current ~140K GSF BSL3 21K GSF BSL4
Greater capacity, more capabilities for supporting medical countermeasure development!
* Image courtesy of CUH2A, the contractor responsible for designing the new USAMRIID facility